## Click here to access the guidelines/NICE algorithm N&WICS - TA664 - Liraglutide - Managing overweight and obesity Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. **Patient Practice** Trust: NHS No: Name: **Patient** Consultant **Practice** Hospital Making Postcode: No: Request: Patient's **Practice** Initials and Code: DoB: Notification Contact Email (@NHS.net account ONLY) name & Address: number: Provider: Start date ☐ Private ☐ NHS of Supplier: Sub-Type: ☐ Homecare ☐ Hospital requested treatment: (if applicable) By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR). For support regarding IFRs, please contact: norfolkicd@nhs.net For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net Please indicate whether patient meets the following NICE criteria: Please tick 1. Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if: • they have a body mass index (BMI) of at least 35 kg/m2 (or at least 32.5 kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and • they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 □Yes □No mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and • they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia and • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and • the company provides it according to the commercial arrangement. 2. As per NICE guidance, treatment should normally be started with the least expensive drug (considering the dose required, price per dose and any additional administration costs). Please confirm that the choice of drug is considered the most cost-effective treatment for this individual

patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.

Where an alternative lower cost treatment is available and has not been tried by the patient, please confirm that the clinical rationale for prescribing has been included in the patients' medical record for the purpose of auditing.

3. The product is being used as described by local commissioning position.

Name of person completing:	Contact Details:
Designation of person completing:	Date:
Trust Authorising Pharmacist	
Date:	